FDA briefing documents show intriguing findings on asymptomatic prevention, though these are based on small numbers.
The Russian-made vaccine posts competitive phase III data – but not on the easily stored formulation.
Relief as two further pandemic vaccines succeed, but the data confirm variants to be a problem.
Merck & Co’s move illustrates how hard it will be for the second wave of Covid-19 vaccine candidates to succeed.
Pivotal data for JNJ-78436735 are imminent, with Novavax and Curevac not far behind.